Aqilion resolves on issue in kind

Aqilion resolves on issue in kind

AQILION AB (publ) is announcing today that the company’s Board of Directors has resolved on an issue in kind in accordance with the acquisition of the Regulus program from LEO Pharma at the end of 2021. The Board was authorized to carry out such a resolution by the Annual General Meeting on June 18, 2021.

Under the agreement with LEO Pharma, Aqilion is to pay a final instalment for the acquisition of the Regulus program when the Phase I clinical trial is approved by issuing 221,527 Aqilion shares to LEO Pharma. The Board has therefore resolved on the issue today according to the agreement, since the Phase I clinical trial was approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK. After the issue, the number of shares in AQILION AB will be 4,430,538 and the share capital will be SEK 2,215,269.

Aqilion focuses on treatments for inflammatory diseases. The company acquired the Regulus program (AQ280), which Aqilion currently runs in-house, from LEO Pharma in December 2021. Aqilion will initially develop AQ280 as a potential treatment for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus. The aim is to start a Phase I safety study with AQ280 in healthy volunteers in the UK in August 2022, followed by a Phase IIa clinical trial in patients. Read more about Aqilion and our pipeline on our website.

For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About Aqilion
Aqilion is a biotech company that focuses on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases. The company is mainly active in the early phases of drug discovery, from idea to early clinical development.

Aqilion combines its experience from major pharmaceutical companies with the drive and entrepreneurship of small growth companies. With solid experience in business development in innovative biotech and pharmaceutical companies, the company’s experienced team and Board of Directors have successfully navigated the process from drug discovery to market.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com